Pfizer is reportedly reevaluating its drug discovery priorities, potentially signaling a strategic shift. The company may be incorporating new approaches, such as genai, to reshape its research and development process. The exact nature and scope of these changes are unclear, but they appear to be part of a broader effort to drive long-term growth.